NASDAQ · STAA

Staar Surgical Co.

$21.57 -$1.81 (-7.74%) 1D Market open

Key Metrics

$1.16B
Market cap
P/E · TTM
$290.38M
Revenue · TTM
−$21.03M
Net income
EPS · TTM $-0.43
Dividend yield
Free cash flow −$54.99M
Beta · 1Y 0.47
EBITDA · TTM −$11.47M
Gross margin 76.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its May 26 high, the share price fell 31%.

    Peak close $33.34 on May 26; trough close $22.95 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -31%
  • Jul 20
    The stock moved -9.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 20
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 9
    The stock moved +20.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.16B
Enterprise value
Shares outstanding49.8M
52-wk range$15.59 – $35.87
Avg volume · 20D770.3K
Net cash
Book value / share$7.14
IndustryOphthalmic Goods
ExchangeNASDAQ
About Staar Surgical Co.
IPO dateJul 7, 1983
Employees957

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S4.01
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 76.9%
Operating -6.7%
Net -7.2%
FCF -18.9%
ROE / ROIC -5.6% · -11.2%

Financial Health

Current ratio5.12
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$251.40M

Cash Flow · TTM

Operating CF −$50.19M
Capex −$4.80M
Free cash flow −$54.99M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

7.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-04-03 · computed by TickerWolf from SEC filings